a b s t r a c t IDH1 (isocitrate dehydrogenase 1) mutations have been identified as early and frequent genetic alterations in astrocytomas, oligodendrogliomas, and oligoastrocytomas as well as secondary glioblastomas. In contrast, primary glioblastomas very rarely contain IDH1 mutations, although primary and secondary glioblastomas are histologically indistinguishable. The IDH1 mutations are remarkably specific to a single codon in the conserved and functionally important Arg132 in IDH1. In gliomas, the most frequent IDH1 mutations (>90%) were G395A (R132H). In this study, we immunized mice with R132H-containing IDH1 (IDH1
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Introduction
Gliomas are the most common primary brain tumors, and are grouped into four grades (grade I-IV) according to the World Health Organization (WHO) criteria. Among them, glioblastomas (GBMs) are the most frequent and malignant type of gliomas [1] . Despite advances in surgical techniques, radiation therapy and adjuvant chemotherapy, their prognoses remain poor: the median survival time for patients with GBMs is only one year [2] . GBMs may occur de novo (primary GBM) or may result from progression of low-grade astrocytomas (secondary GBM) [3, 4] .
An unbiased, genome-wide analysis of the somatic mutations occurring in GBMs revealed recurrent mutations in arginine (amino acid position 132: R132), which is the active site of IDH1, in 12% of tumors analyzed [5] . In the subsequent genetic studies, IDH1 has been found to be mutated in 50-88% of secondary GBMs, whereas only 3-12% of primary GBMs possess these alterations [6] [7] [8] [9] [10] [11] [12] [13] . IDH1 seems to function as a tumor suppressor; therefore, mutated IDH1 contributes to tumorigenesis in part through induction of the HIF-1 pathway [14] . Analyses of progressive glioma samples, including malignant diffuse astrocytomas, anaplastic astrocytomas, well-differentiated oligodendrogliomas, anaplastic oligodendrogliomas, and the mixed oligoastrocytomas, and anaplastic oligoastrocytomas revealed that mutations in IDH1-R132 (IDH1 R132H ) are in fact common (>70%) in these tumors, and also occur less frequently in primary glioblastomas and other cancers [6] [7] [8] [9] [10] [11] [12] [13] . Furthermore, the IDH1 mutation was only rarely detected in any WHO grade I pilocytic astrocytomas [6, 7, 9, 15] , a tumor type with infrequent malignant progression, indicating that these tumors arise through a different mechanism. A monoclonal antibody, which can specifically recognize the IDH1 R132 is urgently needed for both research and clinical purposes. Furthermore, an immunohistochemical assay would be advantageous in the evaluation of the diagnosis and prognosis of a glioma biopsy as well as for biological studies such as evaluating the extent of invasion in mutation-bearing gliomas. In this study, we report a monoclonal antibody, IMab-1, which specifically detects IDH1 R132H in ELISA, Western-blot analysis, and immunohistochemistry. 
Materials and methods
Animals, cell lines, and tissues. Female BALB/c mice were obtained from The Jackson laboratory (Bar Harbor, Maine). Chinese hamster ovary (CHO) and P3U1 cells were obtained from the American Type Culture Collection (ATCC; Manassas, VA). CHO and P3U1 were cultured at 37°C in a humidified atmosphere of 5% CO 2 and 95% air in RPMI 1640 medium including 2 mM L-glutamine (Invitrogen Corp., Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma, St. Louis, MO) and 1% of penicillin-streptomycin solution (Invitrogen Corp.). HOG cells were cultured as described previously [7] . Human tissues slides were obtained from the Tissue Bank at the Preston Robert Tisch Brain Tumor Center at Duke University as described previously [7] . Four anaplastic astrocytoma (WHO Grade III) tissues slides and one diffuse astrocytoma (WHO Grade II) tissue slides, which possess IDH1-R132H mutation (IDH1 R132H ), and two glioblastoma (WHO grade IV) tissues, which do not possess IDH1
R132H
, were previously analyzed [7] .
Hybridoma production. BALB/c mice were immunized by neck s.c. Western-blot analysis. Stable CHO transfectants of IDH1 wt and IDH1 R132H were lysed with lysis buffer (1% Triton X-100 in PBS containing 50 mg/ml aprotinin). HOG cells were transfected with pCMV6 vectors containing the coding sequences of IDH1 wt and five IDH1 mutants, and lysed as described previously [7] . Samples of the supernatant fraction were collected after centrifuging at 15,000g for 5 min. Ten micrograms of the proteins were electrophoresed under reducing conditions on 4-10% NuPAGE gel (Invitrogen). The separated proteins were transferred to a PVDF membrane (Bio-Rad Laboratories, Inc.). After blocking with 5% skim milk in PBS with 0.05% Tween 20, the membrane was incubated with mouse anti-FLAG (M2; 1 lg/ml; Sigma), goat anti- were deparaffinized, rehydrated, and heated at 100°C using citrate buffer (pH 6.0) for 5 min, and incubated first with IMab-1 (5 lg/ml) for 15 min, then with post-primary blocker for 8 min, and finally with polymer for 8 min. Color was developed using 3,3-diaminobenzidine tetrahydrochloride (DAB) for 10 min, and counterstained by hematoxylin.
Results

Production of an anti-IDH1
R132H -specific antibody
We immunized mice with synthetic peptides of IDH1-R132H mutant (IDH1 R132H ). After cell fusion using Sendai virus envelope, the wells of hybridomas, which were producing anti-IDH1 R132H -specific antibodies, were selected in ELISA. After limiting dilution, one of the clones, IMab-1 (IgG 1 subclass) was established. As shown in Fig. 1A 
Specificity of IMab-1 against IDH1 mutants
All IDH1 mutants reported until now were transiently transfected into HOG cells (Fig. 2) 
R132H
-negative gliomas, which were previously characterized [7] . Typical results were shown in Fig. 3 . IMab-1 stained almost all tumor cells of IDH1 R132H -positive gliomas (Fig. 3A, C , and E), whereas no staining was observed in IDH1 R132H -negative gliomas (Fig. 3F) . IMab-1 did not stain endothelial cells or red blood cells in IDH1
-positive gliomas (Fig. 3E) . The concentration-matched isotype control of mouse IgG 1 did not stain any tumor cells (Fig. 3B and D) , although at higher concentrations, non-specific binding of gemistocytes is encountered with this isotype control antibody (data not shown). These results indicate that IMab-1 is useful in immunohistochemistry for detection of IDH1 R132H mutation.
Discussion
The IDH1 gene at 2q33 encodes isocitrate dehydrogenase 1 (IDH1), which catalyzes the oxidative carboxylation of isocitrate to a-ketoglutarate, which leads to the production of NADPH in the citric acid cycle [14] . IDH1 mutations occur frequently in some types of malignant gliomas, and less frequently in other gliomas [7] . To date, all mutations have been identified at the critical isocitrate binding site R132 and the vast majority of changes are heterozygous [6] [7] [8] [9] [10] [11] [12] [13] . In gliomas, mutations in the IDH1 homolog IDH2 have been identified at the aligned R172 [7] . These discoveries mark unique findings in the field of cancer genetics. In this study, we produced an anti-IDH1-R132H (IDH1 R132H )-specific antibody, IMab-1. IMab-1 did not react with wild type of IDH1 (IDH1 wt ) or any other IDH1 mutants in ELISA and Western-blot analysis ( Figs. 1 and 2) . Importantly, using IMab-1, we have developed an immunohistochemical method which allows us to view IDH1 R132H -positive cells in the clinical samples. IMab-1 displays specific cytosolic staining pattern in the tumor cells, whereas shows no staining in normal cells such as endothelial cells or blood cells (Fig. 3) . IDH1 mutations were reported to be very early events, before TP53 mutations or loss of 1p/19q occur [10] , which may lead to diffused staining by IMab-1 in almost every single cell of IDH1 R132H -positive gliomas.
IDH1 is mutated in the majority of secondary GBMs, whereas less than 10% of primary GBMs possess these alterations [7, 10] . IMab-1 can serve as a molecular tool for distinguishing subtypes of GBMs. Furthermore, IMab-1 could help distinguish pilocytic astrocytomas (WHO grade I), which rarely express IDH1 R132H from diffuse astrocytomas (WHO grade II), since these lesions can sometimes be difficult to categorize solely on the basis of histopathological criteria [15] . Most recently, IDH1 mutation have been found in 15 of 187 acute myeloid leukemia samples (AML) [16] . The other tumors, in which IDH1 mutations are reported, are one of colorectal cancer [17] , two prostate cancers [18] , one B-acute lymphoblastic leukemia (B-ALL) [18] , and three adult supratentorial primitive neuroectodermal tumors (sPNET) [6] . IMab-1 might be also useful for diagnosis of these kinds of IDH1 R132H -positive tumors. The R132C mutations (IDH1 R132C ) were observed at high frequency in AML (8/16 IDH1 mutations; 50%), whereas it was observed in only 4% in glioma specimens [16] . In contrast, IDH1 R132H was observed in only 44% of IDH1 mutations in AML, whereas it was observed in 88% in glioma specimens [7] . These results suggest that an anti-IDH1 R132C -specific antibody may be useful for diagnosis of AML as well as glioma subtypes. Therefore, the established anti-IDH1
R132H
-specific monoclonal antibody IMab-1 should be significantly useful for diagnosis and biological evaluation of mutation-bearing gliomas.
